The Australia’s Therapeutic Goods Administration (TGA) has approved the use of tirzepatide, a powerful weight-loss injection for the treatment of obstructive sleep apnoea (OSA) in adults living with obesity.Known commercially as Mounjaro, this glucagon-like peptide-1 (GLP-1) receptor agonist was initially developed to manage type 2 diabetes. Its subsequent approval for chronic weight management had already positioned it as a frontrunner in the global anti-obesity arsenal. Now, with its newest indication, Mounjaro becomes the first drug officially approved to treat OSA in people with obesity a significant advancement in both sleep medicine and obesity care.Obstructive sleep apnea affects nearly 1 billion adults globally and is estimated to impact more than 780,000 Australian adults alone. In the United States, the National Sleep Foundation estimates that around 25 million adults suffer from OSA — many undiagnosed.The disorder occurs when the muscles in the throat relax excessively during sleep, blocking the upper airway and causing breathing to stop and start repeatedly. These interruptions often result in loud snoring, choking sensations, disrupted sleep, and serious daytime fatigue.More than just an inconvenience untreated OSA has been linked to high blood pressure, stroke, heart disease, type 2 diabetes and even cognitive decline. Yet, traditional treatments like CPAP (continuous positive airway pressure) machines and lifestyle changes have been plagued by poor compliance and limited long-term success.Mounjaro’s New Role in Sleep Apnea ManagementThe latest decision by the TGA adds Mounjaro to the small list of pharmacological tools available to combat OSA — but with a twist. The medication doesn’t directly address the mechanics of airway collapse, but instead reduces excess body fat, particularly around the neck, chest, and abdomen, that contributes to upper airway obstruction.This indirect yet impactful approach leverages Mounjaro’s proven efficacy in promoting substantial weight loss, making it particularly relevant to the subset of OSA patients who also struggle with obesity (defined as a BMI of 30 or higher).“Losing weight has long been shown to improve obstructive sleep apnea, and this new indication gives patients a clinically backed tool to help them get there,” says Professor Nick Zwar, a GP and sleep health researcher in Australia.Importance of Lifestyle Change to Treat Sleep ApneaExperts are cautiously optimistic. While Mounjaro’s new approval represents progress, it’s not a cure-all.“Weight-loss drugs like Mounjaro can be life-changing, but they are not substitutes for long-term lifestyle change,” Professor Zwar emphasized. “Patients must still commit to sustainable dietary habits and physical activity to maintain their progress and prevent relapse if they discontinue medication.”This view is echoed by Dr. Moira Junge, CEO of the Sleep Health Foundation, who noted that many individuals with OSA suffer in silence due to limited treatment options. “A pharmacological approach provides hope, especially for those who have struggled with weight loss and CPAP adherence,” she said.Who Can Take Mounjaro for Sleep Apnea?As per the TGA’s updated guidance, Mounjaro is now approved for use in adults with moderate-to-severe obstructive sleep apnea and a BMI of 30 or more. It is not indicated for patients with mild OSA nor for children or adolescents under 18.It cannot be prescribed to individuals with type 1 diabetes, and caution is advised in people with a history of pancreatitis, thyroid tumors, or severe gastrointestinal issues.How Much Does It Cost?Despite the excitement surrounding its approval, access remains a challenge. Mounjaro is currently not subsidized under the Pharmaceutical Benefits Scheme (PBS) in Australia and remains available only via private prescription.The starting monthly cost of the initiation dose is approximately $395 USD, a figure that could place it out of reach for many potential users particularly those from lower socioeconomic backgrounds.In the U.S., where off-label prescription practices are more flexible, it’s anticipated that sleep specialists and primary care doctors may begin evaluating its relevance for similar patient populations, especially as more data becomes available.What Are the Known Side Effects?No medication comes without risks and Mounjaro is no exception. While most people tolerate it well, common side effects include:NauseaUpset stomachConstipation or diarrheaLow blood sugar (especially when used with other diabetes medications)Injection site discomfortThese side effects often diminish over time but serious reactions, although rare, can occur. These include pancreatitis, gallbladder disease, and potential thyroid tumor risks. Hence, it’s critical that the drug be prescribed and monitored by a qualified healthcare professional.This approval highlights a major global trend of the intersection of metabolic health and sleep health and how it is becoming increasingly relevant. With rising rates of obesity, diabetes, and sedentary lifestyles worldwide, the demand for integrated, accessible treatment solutions has never been greater.Although the TGA’s decision currently applies only to Australia, it could influence regulatory bodies in the U.S., Europe, and other parts of the world to consider similar approvals. Already, sleep and obesity researchers across the globe are taking note of this development as a potential shift in OSA treatment paradigms.For millions battling the exhausting cycle of sleep apnea and obesity, this new use for Mounjaro could be a life saver provided it is prescribed responsibly, accessed affordably, and used as part of a long-term wellness plan.